gabapentin has been researched along with Drug Withdrawal Symptoms in 93 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 6-week, randomized, open-label pilot study estimated the treatment effect size of gabapentin (n = 17) compared with bupropion SR (n = 19) for smoking cessation, thereby allowing sample size calculations for a definitive comparison study." | 9.11 | A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. ( Crockford, D; El-Guebaly, N; Patten, S; White, WD, 2005) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 9.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| " First, the maximally effective gabapentin dosage (600-2,700 mg/day) for each patient was determined during an initial dose-titration phase." | 6.72 | Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006) |
| "Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)." | 5.56 | Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020) |
| "This study evaluated the effect of intermittent administration in the development of dependence to diazepam in chronic use of the drug." | 5.38 | Evaluation of anxiolytic effect and withdrawal anxiety in chronic intermittent diazepam treatment in rats. ( Açikmeşe, B; Enginar, N; Hatipoğlu, I; Haznedar, S, 2012) |
| " The primary objective of this study was to compare the efficacy of gabapentin to lorazepam in alleviating sleep disturbances and daytime sleepiness during an episode of alcohol withdrawal." | 5.12 | Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. ( Boyle, E; Malcolm, R; Myrick, LH; Randall, PK; Veatch, LM, 2007) |
| "This 6-week, randomized, open-label pilot study estimated the treatment effect size of gabapentin (n = 17) compared with bupropion SR (n = 19) for smoking cessation, thereby allowing sample size calculations for a definitive comparison study." | 5.11 | A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation. ( Crockford, D; El-Guebaly, N; Patten, S; White, WD, 2005) |
| "Studies in patients with epilepsy undergoing telemetry evaluation for surgery have suggested that discontinuation of carbamazepine (CBZ) is associated with increased seizures." | 5.09 | Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. ( DeToledo, JC; Garofalo, EA; Greiner, M; Lowe, MR; Ramsay, RE, 2000) |
| "Gabapentin, a prescription medication approved for the treatment of seizures and neuralgia, is often prescribed off-label for substance use treatment, mental health problems, and pain." | 3.91 | Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. ( Buttram, ME; Cicero, TJ; Ellis, MS; Kurtz, SP, 2019) |
| "The study showed that gabapentin can significantly prevented opioid-induced hyperalgesia (OIH) induced caused by fentanyl and morphine, suggesting a role for the addition of gabapentin in the perioperative period and during chronic pain treatment as an effective drug to prevent OIH." | 3.78 | Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats. ( Wei, W; Wei, X, 2012) |
| "Gabapentin is an anticonvulsant agent, also effective in the treatment of mood disorders and anxiety disorders." | 3.71 | Treatment of alcohol withdrawal with gabapentin. ( Bozikas, V; Gamvrula, K; Karavatos, A; Petrikis, P; Savvidou, I, 2002) |
| "More gabapentin-treated individuals had no heavy drinking days (12 of 44 participants [27%]) compared with placebo (4 of 46 participants [9%]), a difference of 18." | 2.94 | Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. ( Anton, RF; Book, S; Bristol, E; Hoffman, M; Latham, P; Prisciandaro, J; Voronin, K, 2020) |
| "Gabapentin is an antiepileptic medication with evidence of benefit in alcohol use disorder patients." | 2.82 | Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis. ( Kersten, B; Kunadharaju, R; Mammen, MJ; Mattle, AG; McGrath, P; Sanu, A; Zammit, K, 2022) |
| "Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics." | 2.79 | Gabapentin treatment for alcohol dependence: a randomized clinical trial. ( Begovic, A; Goodell, V; Kyle, M; Mason, BJ; Quello, S; Shadan, F, 2014) |
| "Gabapentin is a potentially useful drug in alleviating the hyperexcitatory painful states in the control of opiate dependence in acute detoxification and the stabilization phase." | 2.78 | The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial. ( Alavinia, M; Moghadam, MS, 2013) |
| "Cannabis withdrawal symptoms were assessed using the Marijuana Withdrawal Checklist." | 2.77 | A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. ( Adusumalli, M; Begovic, A; Buffkins, K; Crean, R; Goodell, V; Kyle, M; Light, JM; Mason, BJ; Quello, S; Rao, S; Shadan, F, 2012) |
| "Improved treatment of alcohol dependence is a high priority, including defining subtypes that might respond differently." | 2.74 | Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. ( Anton, RF; Baros, AM; Latham, PK; Malcolm, R; Myrick, H; Randall, PK; Stewart, SH; Waid, R; Wright, TM, 2009) |
| "Post-treatment, gabapentin-treated participants had less probability of drinking during the follow-up post-treatment period (p = 0." | 2.74 | A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. ( Anton, RF; Becker, HC; Boyle, E; Malcolm, R; Myrick, H; Randall, CL; Randall, PK, 2009) |
| "Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages." | 2.73 | Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. ( Kheirabadi, GR; Maracy, MR; Ranjkesh, M; Salehi, M, 2008) |
| "GABAPENTIN REDUCES WITHDRAWAL SYMPTOMS AND IS LESS SEDATING THAN BENZODIAZEPINES (SOR: B, BASED ON 1 MEDIUM-QUALITY RCT)." | 2.72 | Which detoxification regimens are effective for alcohol withdrawal syndrome? ( Caspar, R; Fortenberry, K; Leiser, J; Nashelsky, J; Ose, D, 2021) |
| " Given its faster onset, increased bioavailability and potency, and nonsaturable absorption, pregabalin's pharmacokinetics theoretically enhance its misuse liability versus gabapentin." | 2.72 | Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. ( Covvey, JR; Evoy, KE; Peckham, AM; Tidgewell, KJ, 2021) |
| " First, the maximally effective gabapentin dosage (600-2,700 mg/day) for each patient was determined during an initial dose-titration phase." | 2.72 | Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006) |
| "Gabapentin is an important adjuvant to the management of opiate dependence both in acute detoxification as well as stabilisation phase." | 2.71 | Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent. ( Jain, MK; Kumar, P, 2003) |
| "Gabapentin is an antiepileptic drug shown to be effective in the treatment of pain disorders and appears to be useful as well for several psychiatric disorders, including bipolar disorder, anxiety disorders, alcohol withdrawal and cocaine dependence." | 2.71 | Add-on gabapentin in the treatment of opiate withdrawal. ( Castellano, M; Cervera, G; Martínez-Raga, J; Perez-Galvez, B; Sabater, A, 2004) |
| " At the time of data cutoff, 30% of patients had withdrawn from the study due to lack of efficacy, and 4% due to adverse events." | 2.67 | The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. ( , 1994) |
| "Gabapentin is a calcium channel GABAergic modulator that is widely used for pain." | 2.58 | Gabapentin for the treatment of alcohol use disorder. ( Mason, BJ; Quello, S; Shadan, F, 2018) |
| "Buprenorphine was superior to clonidine in controlling severe withdrawal symptoms in an outpatient setting (RR 0." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "A history of alcohol or substance abuse appears to be an important part of a patient's medical history when evaluating their risk for addiction and dependence behaviors." | 2.53 | Gabapentin: Abuse, Dependence, and Withdrawal. ( Mersfelder, TL; Nichols, WH, 2016) |
| "Gabapentin may have a role in the treatment of mild alcohol withdrawal, but future studies should focus on adequate dosing strategies." | 2.52 | The role of gabapentin in the management of alcohol withdrawal and dependence. ( Hall-Flavin, D; Leung, JG; Nelson, S; Schak, KM; Schmidt, KA, 2015) |
| "Although some vulvodynia-afflicted patients derive symptom relief from anticonvulsants, there is, as yet, insufficient evidence to support the recommendation of anticonvulsant pharmacotherapy in the treatment of vulvodynia." | 2.49 | A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain. ( Leo, RJ, 2013) |
| "Gabapentin has been studied for diverse off-label indications, including alcohol use disorder (AUD)." | 1.56 | Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach. ( Andrade, C, 2020) |
| "Gabapentin was administered by a nasogastric tube that quickly resulted in a reversal of his symptoms." | 1.51 | Complex encephalopathy arising from the combination of opioids and gabapentin. ( Handa, R; Kak, V; Singh, H; Wasilewski, A, 2019) |
| "Gabapentin has been proved to be beneficial in promoting abstinence, decreasing alcohol cravings, and improving mood and sleep quality when given at higher doses; however, data are limited regarding the efficacy and safety of using high-dose gabapentin as part of the treatment of alcohol withdrawal syndrome (AWS)." | 1.51 | High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis. ( Carrasquillo, L; Ibrahim, D; Levine, AR; Mueller, J; Naut, ER; Nounou, MI, 2019) |
| " Gabapentin misuse is possible, similar to other medications not typically considered drugs of abuse, but it should be considered safe and appropriate for use in patients with all types of SUDs, including patients who take opioid drugs." | 1.40 | Gabapentin for Substance Use Disorders: Is it Safe and Appropriate? ( Howland, RH, 2014) |
| "This study evaluated the effect of intermittent administration in the development of dependence to diazepam in chronic use of the drug." | 1.38 | Evaluation of anxiolytic effect and withdrawal anxiety in chronic intermittent diazepam treatment in rats. ( Açikmeşe, B; Enginar, N; Hatipoğlu, I; Haznedar, S, 2012) |
| "Some patients had no known history of substance abuse." | 1.38 | Gabapentin and pregabalin: abuse and addiction. ( , 2012) |
| "Should the patient experience withdrawal symptoms, the optimal treatment is to restart gabapentin." | 1.37 | Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011) |
| "A patient developed apparent withdrawal symptoms beginning two days after gabapentin therapy was discontinued." | 1.36 | Withdrawal symptoms after gabapentin discontinuation. ( Hammerquist, R; Hellwig, TR; Termaat, J, 2010) |
| "When information became available on aplastic anemia and hepatotoxicity associated with felbamate, all patients were advised to taper their felbamate dosage over approximately 2 weeks." | 1.30 | Increased seizure frequency associated with felbamate withdrawal in adults. ( Privitera, M; Shukla, R; Welty, TE, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (12.90) | 18.2507 |
| 2000's | 25 (26.88) | 29.6817 |
| 2010's | 40 (43.01) | 24.3611 |
| 2020's | 16 (17.20) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, E | 1 |
| Ngo, DH | 1 |
| Espinoza, JA | 1 |
| Beal, LL | 1 |
| Chang, C | 1 |
| Baris, DA | 1 |
| Lackey, BN | 1 |
| Lane, SD | 1 |
| Wu, HE | 1 |
| Bahji, A | 1 |
| Crockford, D | 2 |
| El-Guebaly, N | 2 |
| Mocanu, V | 1 |
| Wood, E | 1 |
| Mattle, AG | 3 |
| McGrath, P | 3 |
| Sanu, A | 3 |
| Kunadharaju, R | 3 |
| Kersten, B | 3 |
| Zammit, K | 3 |
| Mammen, MJ | 3 |
| DeFoster, RE | 1 |
| Morgan, RJ | 1 |
| Leung, JG | 2 |
| Schenzel, H | 1 |
| Vijapura, P | 1 |
| Kashiwagi, DT | 1 |
| Fischer, KM | 1 |
| Philbrick, KL | 1 |
| Kung, S | 1 |
| Buttram, ME | 2 |
| Kurtz, SP | 2 |
| Ellis, MS | 1 |
| Cicero, TJ | 1 |
| Ahmed, S | 1 |
| Stanciu, CN | 1 |
| Kotapati, PV | 1 |
| Ahmed, R | 1 |
| Bhivandkar, S | 1 |
| Khan, AM | 1 |
| Afridi, A | 1 |
| Qureshi, M | 1 |
| Esang, M | 1 |
| Andaluz, A | 1 |
| DeMoss, D | 1 |
| Claassen, C | 1 |
| Blair, S | 1 |
| Hsu, J | 1 |
| Bakre, S | 1 |
| Khan, M | 1 |
| Atem, F | 1 |
| Rush, AJ | 1 |
| Marsden, J | 1 |
| White, M | 1 |
| Annand, F | 1 |
| Burkinshaw, P | 1 |
| Carville, S | 1 |
| Eastwood, B | 1 |
| Kelleher, M | 1 |
| Knight, J | 1 |
| O'Connor, R | 1 |
| Tran, A | 1 |
| Willey, P | 1 |
| Greaves, F | 1 |
| Taylor, S | 1 |
| Modesto-Lowe, V | 1 |
| Barron, GC | 1 |
| Aronow, B | 1 |
| Chaplin, M | 1 |
| Anton, RF | 7 |
| Latham, P | 1 |
| Voronin, K | 3 |
| Book, S | 2 |
| Hoffman, M | 2 |
| Prisciandaro, J | 1 |
| Bristol, E | 2 |
| Cheng, YC | 1 |
| Huang, YC | 1 |
| Huang, WL | 1 |
| Rose, M | 1 |
| Andrade, C | 1 |
| Caspar, R | 1 |
| Fortenberry, K | 1 |
| Leiser, J | 1 |
| Ose, D | 1 |
| Nashelsky, J | 1 |
| Weresch, J | 1 |
| Kirkwood, J | 1 |
| Korownyk, CS | 1 |
| Bertholet, N | 1 |
| Prisciandaro, JJ | 1 |
| Brown, TR | 1 |
| Evoy, KE | 1 |
| Peckham, AM | 1 |
| Covvey, JR | 1 |
| Tidgewell, KJ | 1 |
| Rudolf, G | 1 |
| Walsh, J | 1 |
| Plawman, A | 1 |
| Gianutsos, P | 1 |
| Alto, W | 1 |
| Mancl, L | 1 |
| Rudolf, V | 1 |
| Heeren, N | 1 |
| Farver, D | 1 |
| Mason, BJ | 3 |
| Quello, S | 3 |
| Shadan, F | 3 |
| Sanchez-Alavez, M | 2 |
| Wills, DN | 1 |
| Amodeo, L | 1 |
| Ehlers, CL | 2 |
| Wills, D | 1 |
| Rahimi-Movaghar, A | 1 |
| Gholami, J | 1 |
| Amato, L | 1 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Bonnet, U | 5 |
| Richter, EL | 1 |
| Isbruch, K | 1 |
| Scherbaum, N | 4 |
| Wang, A | 1 |
| Foster, K | 1 |
| Skeba, P | 1 |
| Hiranniramol, K | 1 |
| Earley, CJ | 1 |
| Allen, RP | 1 |
| Morrison, M | 1 |
| Udeh, E | 1 |
| Burak, M | 1 |
| Singh, H | 1 |
| Handa, R | 1 |
| Kak, V | 1 |
| Wasilewski, A | 1 |
| Levine, AR | 1 |
| Carrasquillo, L | 1 |
| Mueller, J | 1 |
| Nounou, MI | 1 |
| Naut, ER | 1 |
| Ibrahim, D | 1 |
| Kim, S | 1 |
| Leo, RJ | 1 |
| Sanders, NC | 1 |
| Mancino, MJ | 1 |
| Gentry, WB | 1 |
| Guise, JB | 1 |
| Bickel, WK | 1 |
| Thostenson, J | 1 |
| Oliveto, AH | 1 |
| Moghadam, MS | 1 |
| Alavinia, M | 1 |
| Goodell, V | 2 |
| Kyle, M | 2 |
| Begovic, A | 2 |
| Howland, RH | 2 |
| Hall-Flavin, D | 1 |
| Nelson, S | 1 |
| Schmidt, KA | 1 |
| Schak, KM | 1 |
| Lee, YI | 1 |
| Chen, L | 1 |
| Smith, RL | 1 |
| Mersfelder, TL | 2 |
| Nichols, WH | 2 |
| Mariani, JJ | 1 |
| Malcolm, RJ | 1 |
| Mamczur, AK | 1 |
| Choi, JC | 1 |
| Brady, R | 1 |
| Nunes, E | 1 |
| Levin, FR | 1 |
| Kheirabadi, GR | 2 |
| Ranjkesh, M | 2 |
| Maracy, MR | 2 |
| Salehi, M | 2 |
| Specka, M | 2 |
| Hamzavi Abedi, R | 1 |
| Wiltfang, J | 1 |
| Myrick, H | 9 |
| Malcolm, R | 4 |
| Randall, PK | 6 |
| Boyle, E | 2 |
| Becker, HC | 1 |
| Randall, CL | 1 |
| Baros, AM | 3 |
| Latham, PK | 3 |
| Wright, TM | 3 |
| Stewart, SH | 1 |
| Waid, R | 1 |
| Hellwig, TR | 1 |
| Hammerquist, R | 1 |
| Termaat, J | 1 |
| Finch, CK | 1 |
| Eason, J | 1 |
| Usery, JB | 1 |
| Schifano, F | 1 |
| D'Offizi, S | 1 |
| Piccione, M | 1 |
| Corazza, O | 1 |
| Deluca, P | 1 |
| Davey, Z | 1 |
| Di Melchiorre, G | 1 |
| Di Furia, L | 1 |
| Farré, M | 1 |
| Flesland, L | 1 |
| Mannonen, M | 1 |
| Majava, A | 1 |
| Pagani, S | 1 |
| Peltoniemi, T | 1 |
| Siemann, H | 1 |
| Skutle, A | 1 |
| Torrens, M | 1 |
| Pezzolesi, C | 1 |
| van der Kreeft, P | 1 |
| Waid, LR | 2 |
| Schacht, JP | 2 |
| See, S | 1 |
| Hendriks, E | 1 |
| Hsiung, L | 1 |
| Wei, X | 1 |
| Wei, W | 1 |
| Açikmeşe, B | 1 |
| Haznedar, S | 1 |
| Hatipoğlu, I | 1 |
| Enginar, N | 1 |
| Crean, R | 1 |
| Light, JM | 1 |
| Buffkins, K | 1 |
| Adusumalli, M | 1 |
| Rao, S | 1 |
| Li, X | 1 |
| Henderson, S | 2 |
| Barrueto, F | 1 |
| Green, J | 1 |
| Howland, MA | 1 |
| Hoffman, RS | 1 |
| Nelson, LS | 1 |
| Drabkin, R | 1 |
| Calhoun, L | 1 |
| Voris, J | 1 |
| Smith, NL | 1 |
| Rao, SM | 1 |
| Thorne, DL | 1 |
| Flowers, QJ | 1 |
| Gustorff, B | 1 |
| Kozek-Langenecker, S | 1 |
| Kress, HG | 1 |
| Banger, M | 2 |
| Leweke, FM | 2 |
| Müller, BW | 1 |
| Hashemi, T | 1 |
| Nyhuis, PW | 1 |
| Kutscher, S | 1 |
| Burtscheidt, W | 1 |
| Gastpar, M | 2 |
| Kumar, P | 1 |
| Jain, MK | 1 |
| Martínez-Raga, J | 1 |
| Sabater, A | 1 |
| Perez-Galvez, B | 1 |
| Castellano, M | 1 |
| Cervera, G | 1 |
| Freye, E | 1 |
| Levy, JV | 1 |
| Partecke, L | 1 |
| Leventhal, L | 1 |
| Cosmi, S | 1 |
| Deecher, D | 1 |
| Book, SW | 1 |
| Tran, KT | 1 |
| Hranicky, D | 1 |
| Lark, T | 1 |
| Jacob, Nj | 1 |
| White, WD | 1 |
| Patten, S | 1 |
| Rodrigues, JP | 1 |
| Edwards, DJ | 1 |
| Walters, SE | 1 |
| Byrnes, ML | 1 |
| Thickbroom, GW | 1 |
| Stell, R | 1 |
| Mastaglia, FL | 1 |
| Himmerich, H | 1 |
| Nickel, T | 1 |
| Dalal, MA | 1 |
| Müller, MB | 1 |
| Anton, R | 1 |
| Wang, W | 1 |
| Victorri-Vigneau, C | 1 |
| Guerlais, M | 1 |
| Jolliet, P | 1 |
| Myrick, LH | 1 |
| Veatch, LM | 1 |
| Furieri, FA | 1 |
| Nakamura-Palacios, EM | 1 |
| Prince, V | 1 |
| Turpin, KR | 1 |
| Markowitz, JS | 1 |
| Finkenbine, R | 1 |
| King, L | 1 |
| Carson, WH | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Watson, WP | 1 |
| Robinson, E | 1 |
| Little, HJ | 2 |
| Bailey, CP | 1 |
| Molleman, A | 1 |
| Corá-Locatelli, G | 1 |
| Greenberg, BD | 1 |
| Martin, JD | 1 |
| Murphy, DL | 1 |
| Welty, TE | 1 |
| Privitera, M | 1 |
| Shukla, R | 1 |
| Brady, KT | 1 |
| Rosebush, PI | 1 |
| MacQueen, GM | 1 |
| Mazurek, MF | 1 |
| Maschke, M | 1 |
| Kowalski, T | 1 |
| Chatterjee, CR | 1 |
| Ringold, AL | 1 |
| DeToledo, JC | 1 |
| Ramsay, RE | 1 |
| Lowe, MR | 1 |
| Greiner, M | 1 |
| Garofalo, EA | 1 |
| Bozikas, V | 1 |
| Petrikis, P | 1 |
| Gamvrula, K | 1 |
| Savvidou, I | 1 |
| Karavatos, A | 1 |
| Covington, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects[NCT02349477] | Phase 2 | 96 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Pattern of Acute Antipsychotic Drug- Toxicity in Children at Assiut University Children Hospital[NCT06125275] | 50 participants (Anticipated) | Observational | 2023-10-30 | Not yet recruiting | |||
| Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial[NCT02771925] | Phase 4 | 25 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to poor compliance of patients in the study.) | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Gabapentin Treatment of Alcohol Dependence[NCT00391716] | Phase 2 | 150 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome[NCT03012815] | Phase 4 | 88 participants (Actual) | Interventional | 2017-02-01 | Completed | ||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-01-10 | Enrolling by invitation | ||
| A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients[NCT00420771] | Phase 2 | 19 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention[NCT00262639] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Gabapentin as an Adjunct to Naltrexone for Alcoholism[NCT00183196] | Phase 3 | 150 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670] | 140 participants (Anticipated) | Interventional | 2018-11-14 | Active, not recruiting | |||
| Gabapentin for Cannabis Withdrawal and Use[NCT00395044] | Phase 2 | 50 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome). (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Low AWS/Gabapentin | 2 |
| Low AWS/Placebo | 3 |
| High AWS/Gabapentin | 10 |
| High AWS/Placebo | 1 |
The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 8 |
| Placebo | 2 |
The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT. (NCT02349477)
Timeframe: 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 12 |
| Placebo | 4 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
Alcohol Craving Questionnaire has 12 questions about alcohol craving which are each scored 1-7, then summed for a weekly score between 7 and 84, with higher scores indicating greater craving. Cumulative mean total craving scores are tested by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 33.66 |
| Gabapentin 1800mg Daily | 32.31 |
| Placebo Daily | 34.27 |
Rate of complete abstinence was defined as the number of participants who drank no alcohol during 12 weeks of treatment, where the denominator is the intent to treat population. Rate of heavy drinking abstinence is defined as no heavy drinking days while on study (4 or more for women, 5 or more for men). (NCT00391716)
Timeframe: 12-week
| Intervention | participants (Number) |
|---|---|
| Gabapentin 900mg Daily | 6 |
| Gabapentin 1800mg Daily | 8 |
| Placebo Daily | 2 |
Beck Depression Inventory II consists of 21 questions assessing depression symptoms answered with scores between 0 and 3, summed for a weekly total score between 0 and 63; higher scores indicate more depression. The cumulative mean total depression scores over the 12 week study are tested by ANOVA for differences in cumulative means between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 5.08 |
| Gabapentin 1800mg Daily | 3.62 |
| Placebo Daily | 5.40 |
The Pittsburgh Sleep Questionnaire Inventory consists of 9 questions about sleep habits which are answered on a scale of 0-3. Results are sorted into 7 sub scales re-scored 0-3, then sub scales are summed for a weekly total score between 0 and 21, with higher total scores indicating greater sleep impairment. Cumulative mean total sleep scores over the 12 weeks of study are assessed by ANOVA for differences between treatment groups. (NCT00391716)
Timeframe: 12-week
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin 900mg Daily | 4.04 |
| Gabapentin 1800mg Daily | 3.24 |
| Placebo Daily | 4.50 |
GAD-7 is GAD-7 is a 7-item self-administered scale of Generalized Anxiety Disorder symptoms (0 = not at all to 3 = nearly every day). Total scores range from 0 to 21. Total scores of 0-4 = minimal anxiety, Total scores of 5-9 = mild anxiety, total scores of 10-14 = moderate anxiety and total scores of 15-21 = severe anxiety. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.07 |
| Benzodiazepine | -3.79 |
PACS is a 5 item self-rated scale of alcohol craving (0 = none to 6 = strong urge). Total scores range from 0 (little craving for alcohol) to 30 (irresistible urge to drink alcohol) (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -8.12 |
| Benzodiazepine | -8.45 |
The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their daytime sleepiness. (NCT03012815)
Timeframe: Baseline and 2 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | -0.03 |
| Benzodiazepine | 0.07 |
CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: 4 days
| Intervention | score on a scale (Mean) |
|---|---|
| Gabapentin | 13.15 |
| Benzodiazepine | 12.81 |
The length of hospital stay for Alcohol withdrawal syndrome. The time interval between admission and either discharge or the time at which Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar) scores are <10 for 36 hours (up to 240 hours). Measured in hours. CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Zero to 7 points are assigned to each item, except for the last item, which is assigned 0-4 points, with a total possible score of 67. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores > 8 represent more withdrawal symptoms and greater severity (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | hours (Mean) |
|---|---|
| Gabapentin | 44.91 |
| Benzodiazepine | 50.50 |
The total amount of benzodiazepines administered. Measured by lorazepam equivalent, mg. (NCT03012815)
Timeframe: Time to discharge or time to CIWA-Ar score < 10 for 36 hours (whichever came first) up to 240 hrs.
| Intervention | milligrams (Mean) |
|---|---|
| Gabapentin | 5.2 |
| Benzodiazepine | 10.8 |
The number of subjects who developed seizure during their hospitalization. (NCT03012815)
Timeframe: During hospitalization (up to 240 hours).
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
The number of participants experiencing delirium tremens during their hospitalization (between admission and discharge). (NCT03012815)
Timeframe: During hospitalization (up to 240 hours)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 0 |
| Benzodiazepine | 0 |
Comparing the mean reduction change in Benzodiazepine use per day when comparing the baseline week prior to study entry to the last week of study participation based on the Time Line Follow Back (NCT00420771)
Timeframe: data collected during 8 weeks of trial or length of participation
| Intervention | milligrams/day (Mean) |
|---|---|
| Active Medication | 4.0 |
| Placebo | 2.3 |
percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6
| Intervention | percent days (Mean) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 70.8 |
| Low CIWAar Placebo | 86.1 |
| High CIWAar Placebo | 75.9 |
| High CIWAar Flumazenil/Gabapentin | 95.9 |
percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial
| Intervention | percent of participants (Number) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 44 |
| Low CIWAar Placebo | 19 |
| High CIWAar Placebo | 33 |
| High CIWAar Flumazenil/Gabapentin | 71 |
Time to relapse drinking which is 5 standard drinks perday for males and 4 standard drinks per day for females. Subjects had a minimum of 4 days of abstinence prior to being entered into the protocol. (NCT00183196)
Timeframe: 16 weeks
| Intervention | days (Mean) |
|---|---|
| Naltrexone Plus Gabapentin and CBI | 69.9 |
| Naltrexone Plus Placebo and CBI | 59.6 |
| Placebo Plus Placebo Plus CBI | 57.3 |
The D-KEFS is a testing battery designed to measure executive functioning, a critical component of participating in cognitive behavioral therapy used to treat marijuana dependence. Data were obtained from the D-KEFS test instruments completed at baseline and week 4, which included the Trail Making Test, Verbal Fluency Test, and Color-Word Interference Test. Scaled scores range from 1 (worst) to 19 (best). Change = (Week 4 score - Week 0 score). Positive values indicate increased executive functioning. (NCT00395044)
Timeframe: Week 0 and Week 4
| Intervention | scores on a scale (Mean) |
|---|---|
| Gabapentin | .28 |
| Placebo | -.20 |
Urinary THC/Cr ratio, also known as CN-THCCOOH (creatinine normalized tetrahydrocannabinol carboxylic acid), is a highly sensitive and specific quantitative analytic procedure to determine current marijuana metabolite levels in the urine as well as new marijuana use or abstinence. Gas chromatography-mass spectrometric levels of 11-nor-9-carboxy-9-THC (THC-COOH), the primary marijuana metabolite, are normalized to the urine creatinine (CN) concentration to reduce the variability of drug measurement attributable to urine dilution. Negative values indicate decreased use. (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | ng/ml (Mean) |
|---|---|
| Gabapentin | -966.00 |
| Placebo | -532.81 |
The MPS is an instrument to assess the incidence of physical, psychological, social, and functioning problems that can result from cannabis dependence. The Total score ranges from 0-38 where 0=best outcome and 38=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -3.40 |
| Placebo | -4.90 |
The Marijuana Craving question of the Marijuana Withdrawal Checklist assesses severity of craving to smoke marijuana. The craving question is rated on a scale of 0-3 where 0=best outcome (no symptoms) and 3=worst outcome (severe symptoms). Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -1.55 |
| Placebo | -1.46 |
The BDI-II is a self-rating of severity of depressive symptoms. The Total score range on the BDI-II is from 0-63; 0=best outcome; 63=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 3.71 |
| Placebo | 5.22 |
The MWC is an instrument to assess the severity of frequently reported cannabis withdrawal symptoms. Each question on the measure is recorded as a severity rating between 0-3: 0=best outcome; 3=worst outcome. The severity rating of each question was averaged to obtain a single marijuana withdrawal severity score. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | 1.42 |
| Placebo | 2.12 |
The PSQI is an instrument to assess subjective sleep quality and disturbance. The range on the measure is from 0-21: 0=best outcome; 21=worst outcome. Change = (Week 12 score - Week 0 score). (NCT00395044)
Timeframe: Week 0 and Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin | -4.27 |
| Placebo | -1.72 |
19 reviews available for gabapentin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review.
Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Gabapentin; Humans; Substance Withdrawal Syndrome | 2022 |
Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review.
Topics: Alcoholism; Anxiety; Anxiety Disorders; Comorbidity; Gabapentin; Humans; Male; Middle Aged; Randomiz | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review.
Topics: Alcoholism; Craving; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Substance Withdrawal Syn | 2019 |
Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England.
Topics: Acetamides; Adolescent; Adult; Aged; Analgesics; Analgesics, Opioid; Antidepressive Agents; Azabicyc | 2019 |
Gabapentin for alcohol use disorder: A good option, or cause for concern?
Topics: Alcohol-Related Disorders; Anticonvulsants; Gabapentin; Humans; Off-Label Use; Risk Assessment; Subs | 2019 |
Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Craving; Gabapentin; Humans; Pregabalin; Randomized Controlled Trials | 2020 |
Which detoxification regimens are effective for alcohol withdrawal syndrome?
Topics: Alcoholism; Anticonvulsants; Benzodiazepines; Carbamazepine; Gabapentin; Humans; Substance Withdrawa | 2021 |
Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
Topics: Area Under Curve; Calcium Channel Blockers; Drug Overdose; Gabapentin; Half-Life; Humans; Metabolic | 2021 |
Gabapentin for the treatment of alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids | 2018 |
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
On the addictive power of gabapentinoids: a mini-review.
Topics: Adult; Amines; Animals; Comorbidity; Craving; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobu | 2018 |
The unsuspected threat of three opioid-like substitutes.
Topics: Analgesics; Antidiarrheals; Gabapentin; Humans; Loperamide; Mitragyna; Opiate Substitution Treatment | 2019 |
A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 2013 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
The role of gabapentin in the management of alcohol withdrawal and dependence.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disease Management; Ethanol; Gabapentin; gamma-Amin | 2015 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Abuse Tr | 2016 |
Novel anticonvulsants in the treatment of alcoholism.
Topics: Alcohol Deterrents; Alcoholism; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
Treatment of alcohol withdrawal syndrome with carbamazepine, gabapentin, and nitrous oxide.
Topics: Amines; Analgesics, Non-Narcotic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Ethan | 2008 |
Anticonvulsants for neuropathic pain and detoxification.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Acids; Gabapenti | 1998 |
28 trials available for gabapentin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Use of Gabapentin for Alcohol Withdrawal Syndrome in the Hospital Setting: A Randomized Open-Label Controlled Trial.
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Benzodiazepines; Gabapentin; Hospitals; Humans; Retr | 2023 |
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal | 2020 |
Effects of Gabapentin on Dorsal Anterior Cingulate Cortex GABA and Glutamate Levels and Their Associations With Abstinence in Alcohol Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Alcoholism; Double-Blind Method; Female; Gabapentin; gamma-Aminobutyric Acid; Glutamic Acid; | 2021 |
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Topics: Adult; Amines; Buprenorphine; Cyclohexanecarboxylic Acids; Diagnostic and Statistical Manual of Ment | 2013 |
The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.
Topics: Adult; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, C | 2013 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Gabapentin treatment for alcohol dependence: a randomized clinical trial.
Topics: Adult; Alcohol Abstinence; Alcoholism; Amines; Central Nervous System Depressants; Cyclohexanecarbox | 2014 |
Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.
Topics: Adolescent; Adult; Aged; Amines; Benzodiazepines; Combined Modality Therapy; Cyclohexanecarboxylic A | 2016 |
Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2008 |
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.
Topics: Adult; Alcohol Drinking; Amines; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Doub | 2009 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedu | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Importance of gabapentin dose in treatment of opioid withdrawal.
Topics: Adult; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2011 |
A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
Topics: Adolescent; Adult; Amines; Calcium Channel Blockers; Cannabis; Counseling; Cyclohexanecarboxylic Aci | 2012 |
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Brain; Cues; Cyclohexanecarboxylic Acids; Drug Therapy, | 2013 |
Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial.
Topics: Acetates; Adult; Alcoholism; Amines; Analysis of Variance; Chi-Square Distribution; Cyclohexanecarbo | 2003 |
Gabapentin in the management of pentazocine dependence: a potent analgesic--anticraving agent.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Anti-Anxiety Agents; Clonidine; Cyclohexanecarboxy | 2003 |
Add-on gabapentin in the treatment of opiate withdrawal.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Female; Gab | 2004 |
Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)--correlation with neurophysiological parameters--.
Topics: Acetates; Adult; Amines; Anesthesia; Anesthetics, Intravenous; Cyclohexanecarboxylic Acids; Electric | 2004 |
A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation.
Topics: Adolescent; Adult; Amines; Bupropion; Cyclohexanecarboxylic Acids; Dopamine Uptake Inhibitors; Excit | 2005 |
Blinded placebo crossover study of gabapentin in primary orthostatic tremor.
Topics: Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Doub | 2006 |
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.
Topics: Adult; Aged; Alcohol-Related Disorders; Alcoholism; Amines; Anticonvulsants; Cyclohexanecarboxylic A | 2007 |
Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin.
Topics: Adult; Aged; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Disorders of Excessive Somnolence; Dou | 2007 |
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Ambulatory Care; Amines; Blood-Brain Barrie | 2007 |
The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blin | 1994 |
Gabapentin treatment of alcohol withdrawal.
Topics: Acetates; Adult; Alcohol Withdrawal Delirium; Alcoholism; Ambulatory Care; Amines; Anticonvulsants; | 1998 |
Treatment of alcohol withdrawal syndrome with gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Central Nervous System Depressants; Chlormethiazole; Cyclo | 1999 |
Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 2000 |
46 other studies available for gabapentin and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
A Retrospective Study of the Adjunctive Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal.
Topics: Alcoholism; Benzodiazepines; Gabapentin; Humans; Retrospective Studies; Substance Withdrawal Syndrom | 2022 |
Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.
Topics: Analgesics; Florida; Gabapentin; Health Personnel; Humans; Interviews as Topic; Off-Label Use; Pain; | 2019 |
Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study.
Topics: Adult; Alcoholism; Benzodiazepines; Drug Tapering; Female; Gabapentin; Humans; Lorazepam; Male; Midd | 2020 |
Gabapentin reduced drinking in patients with alcohol use disorder and alcohol withdrawal symptoms.
Topics: Alcohol Drinking; Alcoholism; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Withdrawal Synd | 2020 |
A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.
Topics: Adult; Analgesics, Opioid; Female; Gabapentin; Humans; Male; Middle Aged; Prescription Drug Misuse; | 2020 |
Gabapentin for Alcohol-Related Disorders: Critical Appraisal of the Symptom-Driven Approach.
Topics: Adult; Alcohol Abstinence; Alcohol-Related Disorders; Alcoholism; Excitatory Amino Acid Antagonists; | 2020 |
Gabapentin for alcohol use disorder.
Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome; Treatment Outcome | 2021 |
Topics: Alcoholism; Gabapentin; Humans; Substance Withdrawal Syndrome | 2021 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids | 2018 |
You Abused What? Getting High with Unique Medications.
Topics: Amines; Anticonvulsants; Antidiarrheals; Antipsychotic Agents; Antitussive Agents; Cyclohexanecarbox | 2017 |
Effect of Gabapentin on Sleep and Event-Related Oscillations (EROs) in Rats Exposed to Chronic Intermittent Ethanol Vapor and Protracted Withdrawal.
Topics: Animals; Brain; Brain Waves; Central Nervous System Depressants; Electroencephalography; Ethanol; Ex | 2018 |
Effect of gabapentin on sleep and delta and theta EEG power in adult rats exposed to chronic intermittent ethanol vapor and protracted withdrawal during adolescence.
Topics: Administration, Inhalation; Age Factors; Alcohol Drinking; Animals; Delta Rhythm; Electroencephalogr | 2018 |
Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period.
Topics: Analgesics; Analgesics, Opioid; Dopamine Agonists; Electromyography; Female; Gabapentin; Humans; Ind | 2018 |
Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal.
Topics: Acute Disease; Adult; Alcoholism; Electronic Health Records; Endpoint Determination; Female; GABA Ag | 2019 |
Complex encephalopathy arising from the combination of opioids and gabapentin.
Topics: Analgesics, Opioid; Brain Diseases; Chronic Pain; Gabapentin; Humans; Male; Middle Aged; Morphine; R | 2019 |
High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis.
Topics: Academic Medical Centers; Adult; Alcohol Withdrawal Delirium; Benzodiazepines; Dose-Response Relatio | 2019 |
Gabapentin for Substance Use Disorders: Is it Safe and Appropriate?
Topics: Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Drug Prescriptions; Gabapentin; gamma-Amin | 2014 |
Gabapentin: can it be misused?
Topics: Amines; Controlled Substances; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric A | 2014 |
Enigmatic Fever and Delirium in a Critically Ill Patient.
Topics: Adult; Amines; Critical Illness; Cyclohexanecarboxylic Acids; Delirium; Fever; Gabapentin; gamma-Ami | 2015 |
Comment: Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Withdraw | 2016 |
Reply: Gabapentin: Abuse, Dependence, and Withdrawal.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Substance Withdraw | 2016 |
Severe protracted alcohol withdrawal syndrome: prevalence and pharmacological treatment at an inpatient detoxification unit--a naturalistic study.
Topics: Adult; Aged; Alcoholism; Amines; Anticonvulsants; Chlormethiazole; Clonazepam; Cyclohexanecarboxylic | 2009 |
Withdrawal symptoms after gabapentin discontinuation.
Topics: Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Ethanol; Female; Gabapentin; | 2010 |
Gabapentin withdrawal syndrome in a post-liver transplant patient.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2010 |
Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.
Topics: Amines; Anticonvulsants; Clonazepam; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Dose-Resp | 2011 |
Akathisia induced by gabapentin withdrawal.
Topics: Aged; Akathisia, Drug-Induced; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, T | 2011 |
Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats.
Topics: Amines; Analgesics, Opioid; Animals; Chronic Pain; Cyclohexanecarboxylic Acids; Drug Tolerance; Fent | 2012 |
Evaluation of anxiolytic effect and withdrawal anxiety in chronic intermittent diazepam treatment in rats.
Topics: Amines; Animals; Anti-Anxiety Agents; Anxiety; Cyclohexanecarboxylic Acids; Diazepam; Disease Models | 2012 |
Gabapentin and pregabalin: abuse and addiction.
Topics: Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Pregabalin; Substa | 2012 |
Gabapentin withdrawal presenting as status epilepticus.
Topics: Acetates; Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2002 |
Anorgasmia and withdrawal syndrome in a woman taking gabapentin.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; H | 2003 |
Gabapentin for the treatment of ethanol withdrawal.
Topics: Acetates; Adult; Alcohol Withdrawal Seizures; Amines; Anticonvulsants; Benzodiazepines; Central Nerv | 2003 |
Gabapentin: the first preemptive anti-hyperalgesic for opioid withdrawal hyperalgesia?
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin; g | 2003 |
Effect of calcium channel modulators on temperature regulation in ovariectomized rats.
Topics: Amines; Animals; Body Temperature Regulation; Calcium Channel Blockers; Calcium Channels; Cyclohexan | 2005 |
Gabapentin withdrawal syndrome in the presence of a taper.
Topics: Aged; Aged, 80 and over; Amines; Antimanic Agents; Bipolar Disorder; Chest Pain; Cyclohexanecarboxyl | 2005 |
[Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal].
Topics: Aged; Alprazolam; Amines; Antimanic Agents; Benzodiazepines; Carbamazepine; Chemical and Drug Induce | 2007 |
Abuse, dependency and withdrawal with gabapentin: a first case report.
Topics: Aged; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
Gabapentin abuse in a cocaine user: implications for treatment?
Topics: Acetates; Adult; Amines; Anticonvulsants; Crack Cocaine; Cyclohexanecarboxylic Acids; Female; Gabape | 1997 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome.
Topics: Acetates; Amines; Animals; Anticonvulsants; Ataxia; Behavior, Animal; Cyclohexanecarboxylic Acids; E | 1997 |
Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption.
Topics: Acetates; Alcoholism; Amines; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarbox | 1998 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
Increased seizure frequency associated with felbamate withdrawal in adults.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Felbamate; Gabapentin; gamma- | 1998 |
Catatonia following gabapentin withdrawal.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Gabapentin | 1999 |
A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin.
Topics: Acetates; Adult; Alcohol Drinking; Alcoholism; Amines; Animals; Anticonvulsants; Comorbidity; Cycloh | 1999 |
Treatment of alcohol withdrawal with gabapentin.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Ethanol; Gabapentin; gamm | 2002 |